Cell & Tissue Preservation Market by Product Type (Cell Cryopreservation, Tissue Cryopreservation), Preservation Method (Slow Freezing, Vitrification), Storage Temperature, Application, End User - Global Forecast 2026-2032
Description
The Cell & Tissue Preservation Market was valued at USD 6.50 billion in 2025 and is projected to grow to USD 7.05 billion in 2026, with a CAGR of 9.35%, reaching USD 12.16 billion by 2032.
An incisive introduction to contemporary challenges and opportunities reshaping cryopreservation and tissue storage across clinical and research ecosystems
The biomedical landscape is experiencing a rapid maturation in preservation science that affects clinical practice, translational research, and biobanking infrastructure. Advances in cryobiology, refined vitrification processes, and improved storage technologies are raising expectations for long-term viability and functional integrity of cells and tissues. Concurrently, the convergence of regenerative medicine, cellular therapies, and precision biology is increasing demand for preservation solutions that can reliably support complex downstream applications such as transplantation, drug discovery, and toxicology studies.
As stakeholders respond to regulatory evolution, supply chain pressures, and shifting reimbursement models, preservation strategies must be evaluated not only for technical performance but also for scalability, cost-efficiency, and compatibility with automated workflows. Emerging requirements around traceability, chain-of-custody, and interoperability with laboratory information systems are reshaping operational priorities in biobanks, clinical facilities, and research institutes. The current moment calls for an integrated view that links product-level choices, application-specific needs, end-user capabilities, preservation methodology, and storage environment decisions to create robust, future-ready preservation programs.
How rapid technological, operational, and strategic shifts are converging to redefine preservation standards and long-term stewardship of biological materials
Several transformative shifts are redefining how organizations approach cell and tissue preservation. Technological refinement in cryoprotectants and cooling protocols is improving viability outcomes and enabling more diverse tissue types to be preserved with functional integrity. Parallel innovations in vitrification and controlled-rate freezing are expanding the practical applicability of preservation across both delicate cell types such as stem cells and structurally complex tissues such as cornea and bone. These technical advances are complemented by digitalization trends that enhance monitoring, predictive maintenance, and remote oversight of storage assets.
Operational and economic forces are also driving change. Clinical adoption of regenerative therapies and the broader use of biobanked specimens for translational research create new expectations for traceability, standardization, and scalability. End users such as hospitals, biobanks, and pharmaceutical companies are adjusting procurement strategies to prioritize reliability and lifecycle cost. At the same time, growing emphasis on sustainability and risk mitigation is encouraging investment in redundant storage models and diversified preservation methods. Together, these shifts are accelerating the integration of preservation strategy into upstream product development, clinical trial planning, and long-term research resource management.
Examining the operational ripple effects and strategic procurement responses prompted by the United States tariffs introduced in 2025
The introduction of tariffs in the United States during 2025 introduced new variables into procurement and supply chain planning for preservation equipment, consumables, and ancillary services. Organizations that rely on imported mechanical freezers, liquid nitrogen handling equipment, and specialized cryoprotectants have had to reassess vendor selection, total landed cost, and inventory policies. As a result, procurement teams are placing greater emphasis on supplier diversification, local sourcing where feasible, and contractual protections that shield operational continuity from trade-driven price volatility.
Beyond direct cost considerations, tariffs are influencing strategic choices around capital investment timelines and the configuration of storage infrastructure. Some institutions are accelerating purchases ahead of tariff milestones to avoid price escalation, while others are evaluating alternative preservation strategies such as increased use of vitrification protocols or longer-term biobanking partnerships to distribute risk. These responses reflect a broader need for resilient procurement frameworks that incorporate scenario planning, supplier performance metrics, and cross-functional alignment between procurement, facilities, clinical operations, and research leadership.
Comprehensive segmentation analysis revealing how product types, applications, end users, preservation methods, and storage environments shape strategic priorities
Segmentation insights illuminate where technical priorities and commercial opportunities intersect across product types, applications, end users, preservation methods, and storage environments. Within product type distinctions, cell cryopreservation encompasses sperm and embryos as well as stem cells, each bringing unique protocol requirements and regulatory considerations, while tissue cryopreservation covers bone and cartilage, cornea, and skin, which demand specific handling and structural preservation approaches. These product-level nuances drive different needs for cryoprotectant selection, cooling rates, and viability assessment techniques.
Application segmentation separates clinical use from research and development, with clinical pathways centering on regenerative medicine and transplantation that require validated, reproducible processes and stringent traceability. Research and development activities such as drug discovery and toxicology studies prioritize throughput, specimen diversity, and compatibility with assay platforms. End users range across biobanks, hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes, each operating under distinct regulatory regimes, budgetary constraints, and operational capacities. Preservation method choices between slow freezing and vitrification shift operational workflows, training needs, and equipment profiles. Storage temperature considerations divide needs between liquid nitrogen systems and mechanical freezers, the latter including chest and upright freezers that influence space planning, access patterns, and maintenance protocols. Mapping these segments against institutional priorities highlights where investments in training, quality assurance, and infrastructure will yield the greatest impact.
Regional dynamics and infrastructure variation across major geographies shaping adoption, regulatory interaction, and preservation infrastructure priorities
Regional dynamics create meaningful variation in technology adoption, regulatory landscapes, and infrastructure maturity across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a mature clinical research ecosystem and developed biobanking networks support rapid adoption of advanced preservation techniques, with emphasis on integration across clinical trials and commercial manufacturing pipelines. Regulatory frameworks and reimbursement pathways influence how institutions prioritize investments in storage infrastructure and quality systems.
The Europe, Middle East & Africa region presents a heterogeneous landscape where leading markets exhibit strong collaborations between academic centers and industry, while other areas focus on expanding basic biobanking capacity and workforce development. Cross-border harmonization initiatives and regional regulatory cooperation can affect specimen movement and collaborative research programs. In Asia-Pacific, high-volume clinical activity and rapid biotechnology sector growth are driving demand for scalable preservation solutions, with an increased focus on automation, cold-chain logistics, and locally tailored support models. Recognition of these regional differences is essential when designing supply strategies, training programs, and regulatory engagement plans that align with local operational realities and future growth vectors.
Strategic company behaviors and collaborative trends that are driving innovation, interoperability, and service-oriented solutions in preservation ecosystems
Key company insights highlight how technology providers, service organizations, and new entrants are influencing preservation capabilities and ecosystem interoperability. Established equipment manufacturers continue to refine freezer design, monitoring systems, and freezer automation, while specialized reagent developers focus on cryoprotectant chemistry and formulation innovation to enhance post-thaw functionality. Service providers and contract organizations are expanding offerings that bundle preservation, storage, and sample logistics into comprehensive solutions that reduce client operational burdens and improve traceability.
Notably, collaboration between device makers and biorepository operators is helping standardize data capture and quality control processes, and partnerships across the supply chain are becoming more common to ensure end-to-end integrity from collection to long-term storage. New entrants, including startups building digital monitoring platforms and modular, scalable storage units, are pushing incumbents to accelerate feature development and interoperability. The competitive landscape rewards companies that combine technical reliability with flexible commercial models, strong validation support, and the ability to integrate into complex clinical and research workflows.
Actionable recommendations for leaders to align preservation strategy with R&D, procurement resilience, workforce capability, digital integration, and strategic partnerships
Industry leaders should prioritize a set of actionable steps to strengthen preservation capabilities while managing risk and unlocking new value streams. First, align preservation strategy with clinical and R&D roadmaps so that storage capability, protocol standardization, and validation plans are proactively embedded into product development timelines and trial designs. Second, diversify procurement channels and establish contingency sourcing to mitigate the impact of trade policy changes and supply chain disruptions; this includes evaluating domestic suppliers, long-term agreements, and shared-service models with partner institutions.
Third, invest in workforce expertise and robust quality systems that ensure consistent application of slow freezing and vitrification protocols across sample types, from sperm and embryos to stem cells and complex tissues like bone and cornea. Fourth, prioritize digital integration and remote monitoring to improve chain-of-custody, predictive maintenance, and compliance reporting. Finally, cultivate strategic collaborations with preservation technology providers, logistics partners, and academic centers to accelerate adoption of best practices and share validation burden. Together, these actions will help organizations balance innovation with operational resilience and regulatory readiness.
A robust, multi-source research approach combining expert interviews, technical literature review, operational case studies, and scenario stress-testing for rigorous insights
The research methodology underpinning this report combined a structured multi-source evidence base with rigorous qualitative synthesis. Primary inputs included expert interviews with stakeholders across clinical labs, biobanking operations, pharmaceutical R&D teams, and equipment providers to capture practical constraints and emergent best practices. Secondary sources encompassed peer-reviewed literature on cryobiology, preservation protocols, storage technologies, and regulatory guidance to ground technical assessments in current science.
Analytical steps involved cross-validating qualitative insights with operational case studies and supplier product specifications to identify reproducible patterns and divergences across preservation methods and storage environments. Scenario analysis was applied to stress-test procurement responses and infrastructure strategies under different trade and supply chain conditions. Quality assurance procedures included triangulation across independent expert viewpoints and iterative review cycles with domain specialists to ensure technical accuracy, clarity, and relevance for decision-makers across clinical, research, and commercial settings.
Synthesis of technical, operational, and strategic implications that position preservation as a critical capability for clinical success and translational research impact
The convergence of technical refinement, operational maturity, and strategic urgency places preservation at the center of future clinical and research success. Improvements in cryoprotectant chemistry and freezing protocols are enabling more reliable preservation across diverse cells and tissues, while innovations in storage hardware and digital monitoring are enhancing traceability and reducing operational risk. At the same time, procurement dynamics, regulatory expectations, and regional infrastructure differences require a nuanced approach that balances technical performance with supply chain resilience and cost-effectiveness.
Organizations that proactively integrate preservation planning into clinical program design, laboratory operations, and corporate procurement will be better positioned to support therapeutic development, biobanking initiatives, and translational research. By focusing on protocol standardization, workforce training, digital integration, and strategic partnerships, stakeholders can transform preservation from a logistical constraint into a strategic capability that underpins clinical outcomes and scientific reproducibility.
Note: PDF & Excel + Online Access - 1 Year
An incisive introduction to contemporary challenges and opportunities reshaping cryopreservation and tissue storage across clinical and research ecosystems
The biomedical landscape is experiencing a rapid maturation in preservation science that affects clinical practice, translational research, and biobanking infrastructure. Advances in cryobiology, refined vitrification processes, and improved storage technologies are raising expectations for long-term viability and functional integrity of cells and tissues. Concurrently, the convergence of regenerative medicine, cellular therapies, and precision biology is increasing demand for preservation solutions that can reliably support complex downstream applications such as transplantation, drug discovery, and toxicology studies.
As stakeholders respond to regulatory evolution, supply chain pressures, and shifting reimbursement models, preservation strategies must be evaluated not only for technical performance but also for scalability, cost-efficiency, and compatibility with automated workflows. Emerging requirements around traceability, chain-of-custody, and interoperability with laboratory information systems are reshaping operational priorities in biobanks, clinical facilities, and research institutes. The current moment calls for an integrated view that links product-level choices, application-specific needs, end-user capabilities, preservation methodology, and storage environment decisions to create robust, future-ready preservation programs.
How rapid technological, operational, and strategic shifts are converging to redefine preservation standards and long-term stewardship of biological materials
Several transformative shifts are redefining how organizations approach cell and tissue preservation. Technological refinement in cryoprotectants and cooling protocols is improving viability outcomes and enabling more diverse tissue types to be preserved with functional integrity. Parallel innovations in vitrification and controlled-rate freezing are expanding the practical applicability of preservation across both delicate cell types such as stem cells and structurally complex tissues such as cornea and bone. These technical advances are complemented by digitalization trends that enhance monitoring, predictive maintenance, and remote oversight of storage assets.
Operational and economic forces are also driving change. Clinical adoption of regenerative therapies and the broader use of biobanked specimens for translational research create new expectations for traceability, standardization, and scalability. End users such as hospitals, biobanks, and pharmaceutical companies are adjusting procurement strategies to prioritize reliability and lifecycle cost. At the same time, growing emphasis on sustainability and risk mitigation is encouraging investment in redundant storage models and diversified preservation methods. Together, these shifts are accelerating the integration of preservation strategy into upstream product development, clinical trial planning, and long-term research resource management.
Examining the operational ripple effects and strategic procurement responses prompted by the United States tariffs introduced in 2025
The introduction of tariffs in the United States during 2025 introduced new variables into procurement and supply chain planning for preservation equipment, consumables, and ancillary services. Organizations that rely on imported mechanical freezers, liquid nitrogen handling equipment, and specialized cryoprotectants have had to reassess vendor selection, total landed cost, and inventory policies. As a result, procurement teams are placing greater emphasis on supplier diversification, local sourcing where feasible, and contractual protections that shield operational continuity from trade-driven price volatility.
Beyond direct cost considerations, tariffs are influencing strategic choices around capital investment timelines and the configuration of storage infrastructure. Some institutions are accelerating purchases ahead of tariff milestones to avoid price escalation, while others are evaluating alternative preservation strategies such as increased use of vitrification protocols or longer-term biobanking partnerships to distribute risk. These responses reflect a broader need for resilient procurement frameworks that incorporate scenario planning, supplier performance metrics, and cross-functional alignment between procurement, facilities, clinical operations, and research leadership.
Comprehensive segmentation analysis revealing how product types, applications, end users, preservation methods, and storage environments shape strategic priorities
Segmentation insights illuminate where technical priorities and commercial opportunities intersect across product types, applications, end users, preservation methods, and storage environments. Within product type distinctions, cell cryopreservation encompasses sperm and embryos as well as stem cells, each bringing unique protocol requirements and regulatory considerations, while tissue cryopreservation covers bone and cartilage, cornea, and skin, which demand specific handling and structural preservation approaches. These product-level nuances drive different needs for cryoprotectant selection, cooling rates, and viability assessment techniques.
Application segmentation separates clinical use from research and development, with clinical pathways centering on regenerative medicine and transplantation that require validated, reproducible processes and stringent traceability. Research and development activities such as drug discovery and toxicology studies prioritize throughput, specimen diversity, and compatibility with assay platforms. End users range across biobanks, hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes, each operating under distinct regulatory regimes, budgetary constraints, and operational capacities. Preservation method choices between slow freezing and vitrification shift operational workflows, training needs, and equipment profiles. Storage temperature considerations divide needs between liquid nitrogen systems and mechanical freezers, the latter including chest and upright freezers that influence space planning, access patterns, and maintenance protocols. Mapping these segments against institutional priorities highlights where investments in training, quality assurance, and infrastructure will yield the greatest impact.
Regional dynamics and infrastructure variation across major geographies shaping adoption, regulatory interaction, and preservation infrastructure priorities
Regional dynamics create meaningful variation in technology adoption, regulatory landscapes, and infrastructure maturity across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a mature clinical research ecosystem and developed biobanking networks support rapid adoption of advanced preservation techniques, with emphasis on integration across clinical trials and commercial manufacturing pipelines. Regulatory frameworks and reimbursement pathways influence how institutions prioritize investments in storage infrastructure and quality systems.
The Europe, Middle East & Africa region presents a heterogeneous landscape where leading markets exhibit strong collaborations between academic centers and industry, while other areas focus on expanding basic biobanking capacity and workforce development. Cross-border harmonization initiatives and regional regulatory cooperation can affect specimen movement and collaborative research programs. In Asia-Pacific, high-volume clinical activity and rapid biotechnology sector growth are driving demand for scalable preservation solutions, with an increased focus on automation, cold-chain logistics, and locally tailored support models. Recognition of these regional differences is essential when designing supply strategies, training programs, and regulatory engagement plans that align with local operational realities and future growth vectors.
Strategic company behaviors and collaborative trends that are driving innovation, interoperability, and service-oriented solutions in preservation ecosystems
Key company insights highlight how technology providers, service organizations, and new entrants are influencing preservation capabilities and ecosystem interoperability. Established equipment manufacturers continue to refine freezer design, monitoring systems, and freezer automation, while specialized reagent developers focus on cryoprotectant chemistry and formulation innovation to enhance post-thaw functionality. Service providers and contract organizations are expanding offerings that bundle preservation, storage, and sample logistics into comprehensive solutions that reduce client operational burdens and improve traceability.
Notably, collaboration between device makers and biorepository operators is helping standardize data capture and quality control processes, and partnerships across the supply chain are becoming more common to ensure end-to-end integrity from collection to long-term storage. New entrants, including startups building digital monitoring platforms and modular, scalable storage units, are pushing incumbents to accelerate feature development and interoperability. The competitive landscape rewards companies that combine technical reliability with flexible commercial models, strong validation support, and the ability to integrate into complex clinical and research workflows.
Actionable recommendations for leaders to align preservation strategy with R&D, procurement resilience, workforce capability, digital integration, and strategic partnerships
Industry leaders should prioritize a set of actionable steps to strengthen preservation capabilities while managing risk and unlocking new value streams. First, align preservation strategy with clinical and R&D roadmaps so that storage capability, protocol standardization, and validation plans are proactively embedded into product development timelines and trial designs. Second, diversify procurement channels and establish contingency sourcing to mitigate the impact of trade policy changes and supply chain disruptions; this includes evaluating domestic suppliers, long-term agreements, and shared-service models with partner institutions.
Third, invest in workforce expertise and robust quality systems that ensure consistent application of slow freezing and vitrification protocols across sample types, from sperm and embryos to stem cells and complex tissues like bone and cornea. Fourth, prioritize digital integration and remote monitoring to improve chain-of-custody, predictive maintenance, and compliance reporting. Finally, cultivate strategic collaborations with preservation technology providers, logistics partners, and academic centers to accelerate adoption of best practices and share validation burden. Together, these actions will help organizations balance innovation with operational resilience and regulatory readiness.
A robust, multi-source research approach combining expert interviews, technical literature review, operational case studies, and scenario stress-testing for rigorous insights
The research methodology underpinning this report combined a structured multi-source evidence base with rigorous qualitative synthesis. Primary inputs included expert interviews with stakeholders across clinical labs, biobanking operations, pharmaceutical R&D teams, and equipment providers to capture practical constraints and emergent best practices. Secondary sources encompassed peer-reviewed literature on cryobiology, preservation protocols, storage technologies, and regulatory guidance to ground technical assessments in current science.
Analytical steps involved cross-validating qualitative insights with operational case studies and supplier product specifications to identify reproducible patterns and divergences across preservation methods and storage environments. Scenario analysis was applied to stress-test procurement responses and infrastructure strategies under different trade and supply chain conditions. Quality assurance procedures included triangulation across independent expert viewpoints and iterative review cycles with domain specialists to ensure technical accuracy, clarity, and relevance for decision-makers across clinical, research, and commercial settings.
Synthesis of technical, operational, and strategic implications that position preservation as a critical capability for clinical success and translational research impact
The convergence of technical refinement, operational maturity, and strategic urgency places preservation at the center of future clinical and research success. Improvements in cryoprotectant chemistry and freezing protocols are enabling more reliable preservation across diverse cells and tissues, while innovations in storage hardware and digital monitoring are enhancing traceability and reducing operational risk. At the same time, procurement dynamics, regulatory expectations, and regional infrastructure differences require a nuanced approach that balances technical performance with supply chain resilience and cost-effectiveness.
Organizations that proactively integrate preservation planning into clinical program design, laboratory operations, and corporate procurement will be better positioned to support therapeutic development, biobanking initiatives, and translational research. By focusing on protocol standardization, workforce training, digital integration, and strategic partnerships, stakeholders can transform preservation from a logistical constraint into a strategic capability that underpins clinical outcomes and scientific reproducibility.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
- 2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
- 3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
- 4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Porter’s Five Forces Analysis
- 4.4. PESTLE Analysis
- 4.5. Market Outlook
- 4.5.1. Near-Term Market Outlook (0–2 Years)
- 4.5.2. Medium-Term Market Outlook (3–5 Years)
- 4.5.3. Long-Term Market Outlook (5–10 Years)
- 4.6. Go-to-Market Strategy
- 5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Cell & Tissue Preservation Market, by Product Type
- 8.1. Cell Cryopreservation
- 8.1.1. Sperm & Embryos
- 8.1.2. Stem Cells
- 8.2. Tissue Cryopreservation
- 8.2.1. Bone & Cartilage
- 8.2.2. Cornea
- 8.2.3. Skin
- 9. Cell & Tissue Preservation Market, by Preservation Method
- 9.1. Slow Freezing
- 9.2. Vitrification
- 10. Cell & Tissue Preservation Market, by Storage Temperature
- 10.1. Liquid Nitrogen
- 10.2. Mechanical Freezers
- 10.2.1. Chest Freezer
- 10.2.2. Upright Freezer
- 11. Cell & Tissue Preservation Market, by Application
- 11.1. Clinical
- 11.1.1. Regenerative Medicine
- 11.1.2. Transplantation
- 11.2. Research & Development
- 11.2.1. Drug Discovery
- 11.2.2. Toxicology Studies
- 12. Cell & Tissue Preservation Market, by End User
- 12.1. Biobanks
- 12.2. Hospitals & Clinics
- 12.3. Pharmaceutical & Biotechnology Companies
- 12.4. Research Institutes
- 13. Cell & Tissue Preservation Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Cell & Tissue Preservation Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Cell & Tissue Preservation Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. United States Cell & Tissue Preservation Market
- 17. China Cell & Tissue Preservation Market
- 18. Competitive Landscape
- 18.1. Market Concentration Analysis, 2025
- 18.1.1. Concentration Ratio (CR)
- 18.1.2. Herfindahl Hirschman Index (HHI)
- 18.2. Recent Developments & Impact Analysis, 2025
- 18.3. Product Portfolio Analysis, 2025
- 18.4. Benchmarking Analysis, 2025
- 18.5. BioLife Solutions, Inc.
- 18.6. CellGenix GmbH
- 18.7. Chart Industries, Inc.
- 18.8. Corning Incorporated
- 18.9. Cryoport, Inc.
- 18.10. Danaher Corporation
- 18.11. Merck KGaA
- 18.12. Panasonic Healthcare Co., Ltd.
- 18.13. PHC Holdings Corporation
- 18.14. Sartorius AG
- 18.15. STEMCELL Technologies Inc.
- 18.16. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
